Foghorn Therapeutics Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K/A	10-K	S-1/A
Revenues [+]	19.2	1.3	0.4	0.0	21.2
Royalties					21.2
Net interest income		-1.9
Revenue growth	1357.8%	206.7%		-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	26.0
Gross profit	19.2	1.3	0.4	0.0	-4.8
Gross margin	100.0%	100.0%	100.0%		-22.7%
Selling, general and administrative [+]	30.7	21.7	11.2	6.7	4.8
General and administrative	30.7	21.7	11.2	6.7	4.8
Research and development	105.6	80.3	57.7	44.4
Other operating expenses					16.4
EBITDA [+]	-113.8	-97.5	-67.2	-50.4	-25.7
EBITDA growth	16.7%	45.1%	33.4%	96.3%
EBITDA margin	-591.9%	-7392.5%	-15628.8%		-120.9%
Depreciation and amortization	3.3	3.2	1.3	0.7	0.4
EBIT [+]	-117.1	-100.7	-68.5	-51.1	-26.0
EBIT growth	16.3%	47.0%	34.2%	96.1%
EBIT margin	-609.2%	-7637.1%	-15937.4%		-122.7%
Interest income, net [+]	5.7	0.1	-1.0	-0.5	-0.4
Interest expense			1.0	0.5	0.4
Interest income	5.7	0.1
Other income (expense), net [+]	2.6	-0.6	0.7	0.5	0.1
Gain (loss) on debt retirement		-1.2	-0.2
Change in fair value of warrants			-0.1	0.0
Other	2.6	2.5			0.3
Pre-tax income	-108.9	-101.3	-68.8	-51.1	-26.3
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-108.9	-101.3	-68.8	-51.1	-26.3
Net margin	-566.3%	-7681.6%	-16000.0%		-124.1%

Basic EPS [+]	($2.62)	($2.73)	($6.23)	($12.20)	($8.94)
Growth	-4.0%	-56.2%	-48.9%	36.5%
Diluted EPS [+]	($2.62)	($2.73)	($6.23)	($12.20)	($8.94)
Growth	-4.0%	-56.2%	-48.9%	36.5%

Shares outstanding (basic) [+]	41.6	37.2	11.0	4.2	2.9
Growth	11.9%	236.5%	163.5%	42.2%
Shares outstanding (diluted) [+]	41.6	37.2	11.0	4.2	2.9
Growth	11.9%	236.5%	163.5%	42.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.